Category Archives: Biotechnology

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017. Unless otherwise stated, all comparisons are for the first quarter 2017 compared to the first quarter 2016. Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss applicable to common stock of $72.9 million, or $1.97 per share, for the first quarter of 2017, compared to a net loss applicable to common stock of $71.0 million, or $2.19 per share, for the first quarter of 2016. Non-GAAP adjusted net loss was $43.1 million, or $1.16 per share, for the first quarter of 2017, compared to non-GAAP adjusted net loss of $41.5 million, or $1.28 per share, for the first quarter of 2016. Non-GAAP adjusted net loss excludes stock-based compensation expense, which represents a significant portion of overall expense and has no impact on the cash position of the Company. For a reconciliation of GAAP net loss to non-GAAP adjusted net loss and GAAP net loss per share to non-GAAP adjusted net loss per share, please see the financial tables at the end of this news release. Net cash used in operating activities for … Continue reading →

The state Biotechnology department has decided to set up a state-of-the-art plant tissue culture laboratory at the Kolkata Biotech Park to enhance production and quality of plants and vegetables. There will be scientists and research fellows who will carry out various kinds of research on plants and bio-fertilizers and how they can be used to increase the production of vegetables in the state. Various medicinal plants will be conserved in the Biotech Park for research purposes. It has been learnt that the department is in the process of formulating the Biotech Policy for Bengal. The state government has already taken the initiative to upgrade the infrastructure of Kolkata Biotech Park, apart from setting up new Biotechnology hubs in Burdwan and Kalimpong. The department has been focusing on the modernisation and expansion of the Common Instrument Facility Centre in the Biotech Park in the city. The department of Biotechnology will obtain all the necessary approvals and clearances to secure funding for the augmentation of the 'Bioincubator Facility' in Kolkata. The department has a plan to conduct research on tissue culture to increase the yield and quality of various products but also to provide germ-free food to the common people. The Biotechnology … Continue reading →

Plandai Biotechnology Inc (OTCMKTS:PLPL)is a up and coming micro cap, and part of thehealth and wellness craze thats all around us. Every outlet who sells food from McDonalds to the local 7Eleven has healthy food choices. Nearly every menu is shiftingfrom things that taste good to things that make you feel better. It seems as though nearly all healthy lifestyle enthusiasts take some sort of powdered form of supplement in the morning to start their day, and Plandai is front and center in this lifestyle change. Itsall about science, chemistry and funding as supplements take a step higher as part of our diet. These are all good things for investors as this health lifestyle sector continues its march to higher levels. It starting to feellike the big four now are cannabis, blockchain/bitcoin, digital media and healthy lifestyle stocks as these sectors mature and begin to break out. Plandai Biotechnology Inc (OTCMKTS:PLPL) announced last week that its highly bioavailable PhytofareCatechin Complex would be the active ingredient in Capital Brands reformulated and soon-to-be released SuperFood Fat Burning Boost, which is used with the brand NutriBullet. Plandas signature brand Phytofarewill make its way to the U.S. and Europe in Coyne Healthcares product Origine … Continue reading →

Barron's ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain Barron's Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ... Direxion Daily S&P Biotech Bear 3X Shares (LABD): The Quick Guide to LABDInvestorplace.com all 38 news articles » Continued here: ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's … Continue reading →

Puma Biotechnology Inc.s stock took a dive last week after its regulatory executive resigned less than three weeks before a U.S. Food and Drug Administration panel is scheduled to review the public companys breast cancer drug Neratinib. The Westwood companys share price dipped 14 percent to $31.38 at the close of business May 5 from $36.45 the day before, when the company notified the Securities and Exchange Commission that Robert Charnas, senior vice president of regulatory affairs and project management, would step down for health reasons effective May 15. The stock was trading at $29.15 when the markets closed Monday. The company, which has a market cap of $1.07 billion, hired 63-year-old Charnas last year with a base salary of more than $330,000, stock options, and a more than $378,000 signing bonus, according to the employment offer letter filed with the SEC. An independent panel of experts is scheduled to review Neratinib for safety and efficacy May 24 before making a recommendation for its use to the FDA. Caroline Anderson is a staff reporter covering retail, restaurants, and hospitality. She can be reached at canderson@labusinessjournal.com. Follow this link: Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review - … Continue reading →

Market Summary Follow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) had a rough trading day for Monday May 08 as shares tumbled 5.54%, or a loss of $-1.7 per share, to close at $29.00. After opening the day at $30.45, shares of Puma Biotechnology Inc traded as high as $31.20 and as low as $28.50. Volume was 1.11 million shares over 8,212 trades, against an average daily volume of 941,762 shares and a total float of 36.97 million. As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.07 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $38.11 and 200-day SMA is $43.37. For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI. Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the … Continue reading →

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology. Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture. Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and … Continue reading →

Puma Biotechnology, Inc. (PBYI) belongs to the Healthcare sector with an industry focus on Biotechnology, with Mr. Alan H. Auerbach as Founder, Chairman, Chief Exec. Officer, Pres and Sec.. The company has been one of the biggest innovators in Biotechnology. Key Statistics: Financials: The company reported an impressive total revenue of 0 in the last fiscal year. If you look at the companys income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, PBYI earned gross profit of 0, in 2015 0 gross profit, while in 2016 Puma Biotechnology, Inc. (PBYI) produced 0 profit. Currently the shares of Puma Biotechnology, Inc. (PBYI) has a trading volume of 4.25 Million shares, with an average trading volume of 1220 shares with shares dropping to a 52 week low of $19.74, and the companys shares hitting a 52 week high of $ 73.27. Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future. Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Puma Biotechnology, Inc. the EPS … Continue reading →

USA Commerce Daily Act On Key Analyst Price Target Shifts: Puma Biotechnology, Inc. (PBYI), Windstream Holdings, Inc. (WIN) USA Commerce Daily Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) are making a strong comeback as they have jumped 55.52% since bottoming out at $19.74 on May. 10, 2016. Meanwhile, due to an ongoing pressure which caused a decline of almost -24.38% in the past ... and more » Read the original: Act On Key Analyst Price Target Shifts: Puma Biotechnology, Inc. (PBYI), Windstream Holdings, Inc. (WIN) - USA Commerce Daily … Continue reading →

What happened Puma Biotechnology(NASDAQ:PBYI) stock has plummeted 18.2% as of 12:53 p.m. EDT following news that Dr. Robert Charnas, its head of regulatory affairs and project management, is hitting the exits ahead of a scheduled Food and Drug Administration (FDA) advisory panel meeting on May 24. Puma Biotechnology has only one product in its clinical-stage drug pipeline, and that drug, neratinib, has been the subject of a lot of scrutiny after trials showed that a large number of patients taking it suffered from high-grade diarrhea. Image source: Getty Images. Puma Biotech's CEO Alan Auerbach hired Charnaslast year to help get neratinib across the regulatory finish line. Previously,Charnas worked at Johnson & Johnson in its research and development department. He was responsible for ongoing development of Zytiga, a prostate cancer drug that J&J acquired in 2009 when it bought Auerbach's previous company, Couger Biotech. Charnas joined Cougar in 2008. Yesterday, Puma Biotech said Charnas is leaving because of health reasons. However, there's some conflicting information circulating that there may have been some disagreements between him and his co-workers. If so, no one is saying for sure what those disagreements were about. News of his departure so close to the FDA advisory … Continue reading →